Outlook Therapeutics Inc. (41O)
XSTU 
Summary
41O Chart
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review
Outlook Therapeutics stock surges 35% after the FDA accepts the resubmitted Lytenava BLA for wet AMD for review, setting a July 29, 2026, decision date.
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.4 per share a year ago.
Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.89 per share a year ago.
Outlook Therapeutics Inc. (41O) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Outlook Therapeutics Inc. ever had a stock split?
Outlook Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Robert Charles Jahr CEO | XSTU Exchange | US69012T3059 ISIN |
| US Country | 17 Employees | 18 Mar 2019 Last Dividend | 14 Mar 2024 Last Split | 13 May 2016 IPO Date |
Overview
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a strong focus on developing and commercializing monoclonal antibodies targeted at a variety of ophthalmic conditions. Originally known as Oncobiologics, Inc., the company underwent a name change to Outlook Therapeutics, Inc. in November 2018, marking a significant redirection of its operational focus. Established in 2010 and headquartered in Iselin, New Jersey, Outlook Therapeutics is dedicated to addressing the unmet medical needs in the field of ophthalmology, leveraging advanced scientific research and strategic collaborations. The company has entered into noteworthy collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd., underscoring its commitment to expanding its research capabilities and enhancing its product portfolio through strategic partnerships.
Products and Services
- ONS-5010
ONS-5010 stands as the lead product candidate of Outlook Therapeutics, representing a significant innovation in the treatment of ophthalmic diseases. It is an ophthalmic formulation of bevacizumab that is specifically designed for the treatment of wet age-related macular degeneration (AMD) along with other retinal diseases. Currently, ONS-5010 is in Phase-III clinical trials, demonstrating Outlook Therapeutics’ dedication to advancing its development through rigorous scientific evaluation. This product aims to offer a new therapeutic option for patients suffering from retinal diseases, potentially improving vision and quality of life for millions globally.
